摘要
目的 探讨p16和nm2 3 H1在胃癌组织中的表达及其与临床病理因素的关系。 方法 应用免疫组化标记链霉菌抗生物素 生物素 (LSAB)方法 ,对 6 5例胃癌患者癌组织中p16和nm2 3 H1蛋白的表达水平进行了检测 ,并对其结果与患者的临床病理资料进行了相关分析。 结果 p16和nm2 3 H1在胃癌组织中的阳性表达率分别为 30 8%、41 5 % ;在分化好的癌组织 ,p16的阳性表达率高于分化差的癌组织 (P <0 0 5 ) ;p16和nm2 3 H1在无淋巴结转移患者的癌组织中阳性率高于有转移者(P <0 0 5、P <0 0 1) ;在Ⅰ、Ⅱ期患者癌组织中高于Ⅲ期患者癌组织 ,差异均有显著性意义 (P <0 0 5、P <0 0 1)。p16蛋白表达阳性者 3年生存率为 45 0 % ,阴性者为 2 8 9% ;nm2 3 H1蛋白表达阳性者 3年生存率为 5 1 9% ,阴性者为 2 1 1% ,阳性表达者与阴性表达者生存率差异有显著性意义 (P <0 0 5 )。p16与nm2 3 H1蛋白的表达率呈正相关 (r=0 0 415 ,P <0 0 5 )。 结论 p16和nm2 3 H1参与了胃癌的发展过程 ,并与胃癌的部分生物学行为有关 。
Objective To study the relationship between the expression of p16 and nm23-H1 and clinicopathology in the patients with gastric cancer. Methods p16 and nm23-H1 protein in cancer tissue of 65 patients were observed with labelled streptavidin biotin (LSAB) immunohistochemical method. Results The total positive rate of p16 and nm23-H1 was 308% and 415% respectively in gastric cancer tissues. The positive expression rate of p16 was significantly higher in well-differentiated cancer than in poorly-differentiated cancer (P<005). The positive expression rate of p16 and nm23-H1 was higher in patients with lymph node metastasis than in those without lymph node metastasis(P<005,P<001) and in clinical stage Ⅰ,Ⅱ than in stage Ⅲ (P<005,P<001).The 3-year survival rate was higher in positive cases of p16 or nm23-H1 protein expression (450%,519%)than in negative ones(289%、211%)(P<005).There was a significants positive correlation between p16 and nm23-H1 protein expression(r=0041*!5,P<005). Conclusions p16 and nm23-H1 may play a role in the development of gastric cancer and be related to partial biological behavior. Expression of p16 and nm23-H1 may serve as a marker for predicting the cancer metastasis and evaluating the prognosis of gastric cancer patients.
出处
《中华外科杂志》
CAS
CSCD
北大核心
2001年第3期229-231,T004,共4页
Chinese Journal of Surgery